Your question#1 is very important. I'm not sure if the AVP-923 will be rejected by FDA because of this issue. Any comments on it will be greatly appreciated. "How do you think the FDA will classify the deaths reported in the STAR trial? Do you anticipate them interpreting them in a similar way to your committee?"